CD36 is currently investigated as a potential therapeutic target in cardiovascular disease (Portal et al., 2016), metabolic syndrome, and obesity (Corpeleijn et al., 2008; Goyenechea et al., 2008). The gene discussed is CD36; the disease is cardiovascular disorder.